# OnCo record prrt-term (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/prrt-term/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "prrt-term" ;
  schema:name "PRRT (peptide receptor radionuclide therapy)"@en ;
  schema:alternateName "PRRT"@en, "peptide receptor radionuclide therapy"@en, "177Lu-DOTATATE"@en, "lutetium DOTATATE"@en, "DOTATATE"@en, "DOTATOC"@en, "somatostatin analogue"@en, "somatostatin analogues"@en, "SSA"@en, "SSAs"@en, "SSTR-targeted"@en, "SSTR imaging"@en, "somatostatin receptor imaging"@en, "alpha PRRT"@en ;
  schema:description "A radioactive drug for neuroendocrine tumours: a small peptide that homes to the somatostatin receptor on the tumour cells carries lutetium-177, which irradiates them from within. Given four times, two months apart."@en ;
  schema:url <https://onco.cc/terms/prrt-term/> ;
  schema:dateModified "2026-09-09"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Peptide_receptor_radionuclide_therapy> ;
  schema:citation <https://en.wikipedia.org/wiki/Peptide_receptor_radionuclide_therapy> ;
  onco:related <https://onco.cc/technologies/prrt/>, <https://onco.cc/terms/theranostics/>, <https://onco.cc/terms/dosimetry/>, <https://onco.cc/technologies/radioiodine-therapy/>, <https://onco.cc/terms/alpha-vs-beta/> ;
  onco:cancers <https://onco.cc/cancers/neuroendocrine/> ;
  onco:sections <https://onco.cc/fronts/radiopharma/> ;
  onco:technologies <https://onco.cc/technologies/radioligand-therapy/>, <https://onco.cc/technologies/targeted-alpha-therapy/> ;
  onco:targets <https://onco.cc/targets/sstr2/> ;
  onco:drugs <https://onco.cc/drugs/ga68-dotatate/> .